Schrödinger, Inc. (Nasdaq: SDGR) has announced initial clinical data from its ongoing Phase 1, open-label, dose-escalation study of SGR-1505, targeting patients with relapsed/refractory B-cell malignancies. The study results, which were presented at the European Hematology Association Annual Congress, indicate that SGR-1505 is safe, well tolerated, and shows clinical activity, with responses noted in various histologies including chronic lymphocytic leukemia and Waldenström macroglobulinemia. As of May 13, 2025, 49 patients were enrolled and evaluable for safety. Schrödinger's management will host a webcast to discuss these findings and the proposed Phase 2 dose later today.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Schrodinger Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250612910362) on June 12, 2025, and is solely responsible for the information contained therein.